Navigation Links
Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

    -- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with

       Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute

       Leukemias Treated with SNS-595" will be presented on Saturday, June 9,

       2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical

       II poster session.

    -- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based

       Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from

       Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial"

       will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during

       the Novel Therapeutics and Targeted Therapies poster session.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first hal f of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. For further information on Sunesis Pharmaceuticals, please visit

CONTACT: Investors, Eric Bjerkholt, SVP, Corporate Development & Financeof Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Karen L. Bergman,+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners,for Sunesis Pharmaceuticals, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:SNSS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):